Am­gen shelves ear­ly-stage bis­pe­cif­ic T cell en­gager

Am­gen has stopped de­vel­op­ment of a Phase 1 bis­pe­cif­ic T cell en­gager, a type of med­i­cine that is core to its on­col­o­gy port­fo­lio and for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.